Dogwood Therapeutics (DWTX) Return on Capital Employed (2021 - 2026)
Dogwood Therapeutics (DWTX) posted quarterly Return on Capital Employed of 31.75% for Q1 2026, down 1526.0% year-over-year from 2.23% in Q1 2025, and little changed quarter-over-quarter from 31.77% in Q4 2025.
Dogwood Therapeutics (DWTX) Return on Capital Employed (2021 - 2026) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported Return on Capital Employed for 6 consecutive years, with 31.75% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 1526.0% year-over-year to 31.75%; the TTM figure through Mar 2026 stood at 31.75% (down 1526.0% YoY), while the FY2025 annual figure was 31.36%, down 482.0% from the prior year.
- Return on Capital Employed was little changed at 31.75% in Q1 2026 per DWTX's latest filing, from 31.77% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 16.49% in Q1 2025 and bottomed at 358.19% in Q3 2024.
- Historically, Return on Capital Employed has averaged 119.3% across 5 years, with a median of 134.89% in 2023.
- Annual changes were most pronounced in 2024 — Return on Capital Employed tumbled 22329 bps — and 2025, when it soared 32363 bps.
- Dogwood Therapeutics' Return on Capital Employed stood at 143.69% in 2022, then climbed by 13 bps to 125.26% in 2023, then soared by 78 bps to 27.1% in 2024, then fell by 17 bps to 31.77% in 2025, then increased by 0 bps to 31.75% in 2026.
- Business Quant data shows DWTX's Return on Capital Employed at 31.75% in Q1 2026, 31.77% in Q4 2025, and 34.56% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Dogwood Therapeutics | 84.98 Mn | 84.98 Mn | - | -45.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31.75% |
| Dec 31, 2025 | -31.77% |
| Sep 30, 2025 | -34.56% |
| Jun 30, 2025 | -19.16% |
| Mar 31, 2025 | -16.49% |
| Dec 31, 2024 | -27.10% |
| Sep 30, 2024 | -358.19% |
| Jun 30, 2024 | -163.69% |
| Mar 31, 2024 | -166.52% |
| Dec 31, 2023 | -125.26% |
| Sep 30, 2023 | -134.89% |
| Jun 30, 2023 | -144.33% |
| Mar 31, 2023 | -143.73% |
| Dec 31, 2022 | -143.69% |
| Sep 30, 2022 | -173.32% |
| Jun 30, 2022 | -179.07% |
| Mar 31, 2022 | -134.66% |
| Dec 31, 2021 | -93.85% |
| Sep 30, 2021 | -86.31% |
| Jun 30, 2021 | -65.41% |